Effects of Biphasic Insulin Aspart 70/30 vs. Exenatide in Type 2 Diabetes Patients Not Reaching Blood Glucose Targets on Metformin and a Sulfonylurea.

NCT00313001 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

373

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes
Diabetes Mellitus, Type 2

Interventions

DRUG: biphasic insulin aspart
DRUG: exenatide

Sponsor

Novo Nordisk A/S